Natco Pharma Sustainability Profile
Natco Pharma Limited, headquartered in Hyderabad, India, is a prominent player in the pharmaceutical industry, specialising in the development, manufacturing, and marketing of generic and specialty medicines. Founded in 1981, the company has achieved significant milestones, including the launch of several high-quality generic formulations and active pharmaceutical ingredients (APIs) that cater to various therapeutic areas such as oncology, cardiology, and neurology. With a strong presence in both domestic and international markets, Natco Pharma is recognised for its commitment to innovation and affordability. The company’s core products, including complex generics and biosimilars, stand out due to their quality and accessibility. Natco's strategic focus on research and development has positioned it as a leader in the pharmaceutical sector, earning accolades for its contributions to healthcare and patient well-being.
DitchCarbon Score
How does Natco Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Natco Pharma's score of 29 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Natco Pharma's reported carbon emissions
In 2025, Natco Pharma reported total carbon emissions of approximately 67,265,460 kg CO2e, comprising about 23,395,110 kg CO2e from Scope 1 and about 43,630,350 kg CO2e from Scope 2 emissions. For the previous year, 2024, the company recorded emissions of about 62,818,720 kg CO2e, with Scope 1 emissions at approximately 20,898,100 kg CO2e and Scope 2 emissions at about 41,763,620 kg CO2e. Natco Pharma has set ambitious long-term targets to enhance renewable energy (RE) in its energy mix, aiming for a 35% increase by the end of 2035 for both Scope 1 and Scope 2 emissions. This commitment reflects the company's proactive approach to reducing its carbon footprint and transitioning towards more sustainable energy sources. The company has not disclosed any Scope 3 emissions data, indicating a potential area for future reporting and improvement. Overall, Natco Pharma's climate commitments and emissions data demonstrate a clear focus on sustainability and reducing environmental impact within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Scope 1 | 13,265,000 | 00,000,000 | 000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 44,696,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - |
How Carbon Intensive is Natco Pharma's Industry?
How Carbon Intensive is Natco Pharma's Location?
Natco Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Natco Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
